Compare Salesforce Inc (CRM) vs Heron Therapeutics Inc (HRTX) Price & Performance

Salesforce (CRM) trades at $171.22, up 4.84% today, but remains down significantly year-to-date amid a broader software sell-off. The company demonstrates strong fundamentals with revenue growth to $37.90B in 2025 and a net income margin of 18.73%. Recent quarters show consistent earnings beats, and analyst consensus remains strongly bullish with a $235.90 price target. Technical indicators are mixed, with the stock near key support at $167.

The outlook is positive for long-term investors given robust profitability, AI-driven growth initiatives, and a discounted valuation. Key risks include intense competition in the SaaS sector and macroeconomic sensitivity. The current price presents a potential entry point relative to analyst targets, but volatility may persist in the near term.

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.